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Cognitive Behavior Therapy (CBT) and Mindfulness-Based Cognitive Therapy (MBCT)
have shown to be effective interventions for treating depressive symptoms in patients with
diabetes. However, little is known about which intervention works best for whom (i.e., mod-
erators of efficacy). The aim of this study was to identify variables that differentially predicted
response to either CBT or MBCT (i.e., prescriptive predictors).
Methods
The sample consisted of 91 adult outpatients with type 1 or type 2 diabetes and comorbid
depressive symptoms (i.e., BDI-II 14) who were randomized to either individual 8-week
CBT (n = 45) or individual 8-week MBCT (n = 46). Patients were followed for a year and
depressive symptoms were measured at pre-treatment, post-treatment, and at 9-months
follow-up. The predictive effect of demographics, depression related characteristics, and
disease specific characteristics on change in depressive symptoms was assessed by
means of hierarchical regression analyses.
Results
Analyses showed that education was the only factor that differentially predicted a decrease
in depressive symptoms directly after the interventions. At post-treatment, individuals with
higher educational attainment responded better to MBCT, as compared to CBT. Yet, this
effect was not apparent at 9-months follow-up.







Citation: Tovote KA, Schroevers MJ, Snippe E,
Emmelkamp PMG, Links TP, Sanderman R, et al.
(2017) What works best for whom? Cognitive
Behavior Therapy and Mindfulness-Based
Cognitive Therapy for depressive symptoms in
patients with diabetes. PLoS ONE 12(6): e0179941.
https://doi.org/10.1371/journal.pone.0179941
Editor: Terence J. Quinn, University of Glasgow,
UNITED KINGDOM
Received: August 16, 2016
Accepted: June 4, 2017
Published: June 29, 2017
Copyright: © 2017 Tovote et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: No specific funding was obtained; the
study was financed by the University of Groningen
and University Medical Center Groningen.
Therefore, the funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
Conclusions
This study did not identify variables that robustly differentially predicted treatment effective-
ness of CBT and MBCT, indicating that both CBT and MBCT are accessible interventions
that are effective for treating depressive symptoms in broad populations with diabetes. More
research is needed to guide patient-treatment matching in clinical practice.
Introduction
Depression and diabetes are common coexisting conditions that have a debilitating impact on
each other [1]. As diabetes not only negatively affects patients’ physical health but also their
mental health, a substantive number of patients suffers from depressive symptoms [2,3]. Cog-
nitive Behavior Therapy (CBT) is the most commonly used evidence-based psychological
intervention for treating depressive symptoms in individuals with and without a chronic
somatic disease [4–6]. In the past decade, Mindfulness-Based Cognitive Therapy (MBCT) has
evolved as an upcoming therapy for treating depressive symptoms [7]. Although the field of
research on MBCT for current depressive symptoms is still relatively young, existing studies
have provided consistent empirical support for the effectiveness of MBCT in reducing depres-
sive symptoms and increasing quality of life in healthy as well as in chronically ill people [8–
10].
CBT and MBCT can be characterized as variants of cognitive therapy, but they do include
fundamentally different treatment techniques. CBT is a structured program that focuses on
behavioral activation and on helping patients to understand connections among thoughts, feel-
ings, and behaviors in order to consequently alter underlying cognitions that maintain a
depressed mood [11]. MBCT, on the contrary, involves practicing awareness and acceptance
of dysfunctional thoughts, feelings, and bodily sensations by focusing on the present moment
during mindfulness meditation and yoga exercises [7]. Because of the different focus of CBT
and MBCT, it could be that these treatments are beneficial for different groups of patients.
A few studies have directly compared the effects of CBT and mindfulness-based interven-
tions [12–15]. Those studies provided evidence for the effectiveness of both interventions with
respect to improving a variety of psychological and medical outcomes. In a recent randomized
controlled trial, we compared the effects of individual CBT and MBCT in reducing depressive
symptoms in comparison to a waiting list control condition in patients with diabetes [16].
Both interventions were found to be effective in reducing depressive symptoms, diabetes-
related distress, and anxiety as well as in increasing well-being, with no intervention being
superior over the other. Positive effects sustained at long-term follow-up at nine months after
treatment [17].
This evidence, suggesting comparable effectiveness of both CBT and MBCT, does not nec-
essarily imply that every individual patient benefits equally from these interventions. Charac-
teristics of the individuals presenting for treatment are assumed to impact the level of
treatment efficacy [18,19]. The current study investigates factors that predict differential
response to CBT and MBCT.
Much of the literature on predictors of treatment efficacy has focused on investigating gen-
eral prognostic predictors of CBT in order to identify subpopulations of patients that are most
likely to benefit from CBT [20,21]. Typically, these studies have investigated predictors
grouped in four different domains, namely demographics, clinical characteristics, personality
dimensions, and disease related characteristics in somatic populations. Although
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demographics as predictors for CBT outcome have widely been studied, results are inconclusive
as to which characteristics are of influence. Whereas some studies identified age [22], gender
[23,24], education [22,23], marital status [22,25] as predictors, other studies failed to identify
any demographic predictors [26–28]. In contrast, clinical characteristics such as high levels of
pretreatment depressive symptoms, chronicity, and history of depression have consistently
been associated with poorer CBT treatment outcome [20,27,29]. Studies that investigated per-
sonality dimensions as possible predictors of outcome mainly focused on neuroticism [30].
Again, no clear pattern emerged in the literature. Although high levels of neuroticism were asso-
ciated with poor CBT outcome in some empirical studies [30–32], an earlier review by Mulder
et al. [30] concluded that the influence of neuroticism firmly depended on the methodology of
the study as the strongest support for the association came from methodologically weaker stud-
ies. Finally, disease-related variables like type of treatment, comorbidity, and diabetes-related
distress may also predict outcome to psychological treatment. Lustman et al. [33] found that
CBT was overall effective in reducing depressive symptoms, but that patients scoring lower on
compliance with self-monitoring of blood glucose (SMBG) and with presence of diabetes com-
plications achieved less remission of depressive symptoms than did patients with higher compli-
ance with SMBG and no diabetes complications. Accordingly, diabetes symptom burden or
diabetes-related distress might interfere with depression treatment and thereby negatively influ-
ence its effectiveness.
Comparatively, fewer studies have been conducted examining potential predictors of
MBCT outcome and of these studies, the majority focused on recurrently depressed patients in
remission. Kuyken et al. [34], investigated several possible general prognostic predictors like
demographics, severity of depression, and depression recurrence and found that only gender
was a significant predictor. Female participants showed a greater reduction in depressive
symptoms at 15-months follow-up as compared to males. Yet, as the number of males in the
study was low, the result should be replicated before drawing firm conclusions. In addition,
another study by Nyklicek et al. [35] also found that females showed larger decreases in depres-
sion after MBCT as compared to males. Prior research by Teasdale and colleagues [36,37]
reported that for patients with three or more previous depressive episodes, MBCT significantly
decreased the risk of relapse, whereas this was not the case for participants with fewer episodes.
Another study focusing on personality factors as predictors found that students had more ben-
efit from Mindfulness-Based Stress Reduction when scoring high on neuroticism [38]. Hence,
given the scarcity of previous research, firm conclusions about prognostic indicators of
response to MBCT cannot be drawn.
Identifying general prognostic predictors within a given treatment may provide indications
about who benefits most from that treatment, yet it offers no information on which type of
treatment is more effective for a patient with certain characteristics. In this context, it is impor-
tant to consider the interaction between patient characteristics and treatment modality by
comparing active treatments with each other. The identification of those so-called prescriptive
predictors, or moderators, can indicate subpopulations that fare better with one treatment
than the other. Gaining insight into which treatment works best for whom can enhance opti-
mal treatment selection, resulting in optimized clinical decision making and a more personal-
ized care.
To date, only three RCTs investigated prescriptive predictors of CBT and mindfulness-
based interventions. Manicavasagar et al. [14], investigating the effectiveness of MBCT and
CBT for individuals with major depressive disorder, revealed differential effects for history of
depression. CBT was more effective for individuals with four or more episodes, while MBCT
was equally effective irrespective of the number of previous episodes. Arch et al. [13], although
not focusing on depression but on individuals with anxiety, found that severity of current
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depressive symptoms was a moderator of effectiveness: individuals with no to mild depression
had more benefit from CBT, whereas people with moderate to severe depression fared better
with the mindfulness intervention. In another study, Zautra et al. [15] compared the effects of
CBT and a mindfulness intervention to an education group with respect to several psychologi-
cal and pain-related outcomes in a non-clinical sample of patients with rheumatoid arthritis. It
was revealed that patients with recurrent depressive symptoms had most benefit from the
mindfulness intervention. Unfortunately, these studies focused on clinical characteristics only,
while other characteristics such as demographics, disease-related characteristics, and personal-
ity may also differentially predict change after treatment [18].
To advance the knowledge of prescriptive predictors (i.e., moderators) of the effects of CBT
and MBCT, the current study investigated a broad range of patient characteristics to identify
prognostic and prescriptive predictors in CBT and MBCT for depressive symptoms in patients
with diabetes. We examined clinical meaningful patient characteristics that can be easily
assessed by clinicians, namely demographics, clinical characteristics, neuroticism, and diabetes
related characteristics. First, we examined which patient characteristics differentially predicted
response to CBT and MBCT. Second, we investigated potential prognostic predictors sepa-
rately for CBT and MBCT. While no clear hypotheses were formulated with respect to demo-
graphic, clinical, and disease specific characteristics, we hypothesized that patients scoring
high on neuroticism will benefit more from MBCT as compared to CBT.
Materials and methods
Study design
The present study was embedded in a longitudinal multi-center, randomized controlled trial
in which CBT and MBCT were compared to a waiting list control condition in terms of their
effectiveness in reducing depressive symptoms (NCT01630512, ClinicalTrials.gov; the study
was not registered before participants were included as it was then not mandatory to register
non-drug intervention studies in the Netherlands. We registered the study immediately after
we were notified of its importance). The study was approved by the Medical Ethical Commit-
tee of the University Medical Center Groningen (UMCG) on May, 18th 2011 (S1 File) and
compiled with the declaration of Helsinki and the CONSORT statement (S2 File). For an
extensive description of the study procedures, the reader is referred to the original publication
of the study protocol [39]. The authors confirm that all ongoing and related trials for this inter-
vention are registered.
Participants
Included participants were 18–70 years old with type 1 or 2 diabetes diagnosed at least three
months prior to inclusion who had depressive symptoms as assessed with the BDI-II (cut off
score 14 indicating the presence of at least mild symptoms of depression). Patients were
excluded if they were not able to read and write, were pregnant, had a severe psychiatric
comorbidity (including acute suicidal ideations), were receiving an alternative psychological
treatment, or had started or altered their dosage of antidepressant drug within two months
prior to participation.
Procedure
Patient recruitment took place from June 2011 to February 2013 and the last follow-up was
concluded in April 2014. The trial was conducted in the Netherlands and included 94 partici-
pants. The patient flow is shown in Fig 1. Patients were recruited through standard screening
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at somatic outpatient clinics, referral by physician, and self-referral. In case of elevated levels of
depressive symptoms, patients were invited for an intake during which they were assessed for
eligibility. When criteria were met and patients gave written informed consent for
Fig 1. Flow of the study.
https://doi.org/10.1371/journal.pone.0179941.g001
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participation, they were included in the study. Computerized randomization was carried out
stratified by gender, use of antidepressant medication, and baseline BDI-II score. Before ran-
domization, patients were blinded for the treatment condition. Consequently, patients were
only told that they were to be randomized to a psychological treatment for reducing depres-
sion, starting within three months after randomization. Researchers performed the randomi-
zation and informed the participants. Following randomization, participants received
individual CBT (n = 32), individual MBCT (n = 31), or were allocated to a waiting list control
condition (n = 31). Patients allocated to the control group were randomized for the second
time at the end of the three-months waiting period and received either CBT (n = 15) or MBCT
(n = 16). For the purpose of the present study, participants in the waiting list condition were
included in the analyses on condition that patients still had elevated levels of depressive symp-
toms after the waiting period (i.e., BDI-II 14). Three of the 31 patients did not score above
the cut-off and were excluded, resulting in a total sample of 91 participants.
Treatments
CBT and MBCT consisted of eight weekly outpatient treatment sessions of 45 to 60 minutes.
Treatment was delivered individually by trained therapists that received supervision during
the study period. Patients were expected to spend about 30 minutes per day on homework
assignments. The CBT manual was based on CBT for depression developed by Beck [11]. The
length of the training was shortened to eight sessions, to match the setting of the two treat-
ments and to ensure a fit with the Dutch healthcare system. The MBCT treatment manual was
based on the protocol developed by Segal, Teasdale and Williams [7]. As this protocol is devel-
oped as a 2.5-hour per session group treatment, we developed a shortened and individualized
version of this protocol. This protocol has previously been tested in a pilot study in patients
with diabetes and was evaluated as feasible and acceptable [40].
Outcome measure
The primary outcome measure was change in depressive symptoms, assessed with the Beck
Depression Inventory-II (BDI-II) [41] at pre-treatment, post-treatment (i.e. on average three
months after pre-treatment), and at 9-months follow-up (i.e. on average 12 months after pre-
treatment). The BDI-II consists of 21 items that are scored on a four-point scale from 0 (“not
at all”) to 3 (“most of the time”). The items assess symptoms of depression such as sadness, loss
of interest, and hopelessness during the last two weeks. Item scores are summated with a maxi-
mum score of 63. A BDI-II score of 14 indicates mild depressive symptoms. The reliability
of the BDI-II was good in the current study (range α = 0.84–0.94).
Predictor variables
Following the recommendations of Fournier et al. [22], we analyzed prospective predictors in
different domains. All potential predictors and moderators of change were assessed before ran-
domization at pre-treatment. Data were obtained from self-report questionnaires, intake inter-
views, and patients’ medical records.
Domain 1: Demographic characteristics. The following socio-demographic characteris-
tics were included in the first domain: age (continuous), gender (dichotomous; (0) male, (1)
female), education (three levels: lower level vocational school, secondary education/advanced
level vocational school, higher or university education, coded into two dummy variables; (1)
low levels of education, (2) high levels of education), employment (dichotomous; (0) unem-
ployed, (1) employed), and marital status (dichotomous; (0) not in a relationship, (1) in a rela-
tionship). All variables were assessed by means of self-report.
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Domain 2: Clinical characteristics and personality. The second domain consisted of cur-
rent major depression, history of depression, history of psychological care, and neuroticism.
Current major depression and history of depression were assessed during the intake by means
of the depression section of the Structured Clinical Interview for DSM-IV (SCID-I) [42]. The
output of the SCID was recorded as the presence (coded as 1) or absence (coded as 0) of a cur-
rent or a past depressive episode. History of psychological care (i.e., psychologist or psychiatrist)
was also assessed during the intake (dichotomous; (0) no history of care, (1) history of care). As
neuroticism is strongly related to characteristics of depression, it was included in this domain.
Neuroticism was assessed as a continuous variable by the subscale of the NEO- Five Factor
Inventory (NEO-FFI) [43]. The internal consistency was good in the current study (α = 0.78).
Domain 3: Disease specific characteristics. The final domain, disease specific characteris-
tics, included type of diabetes (dichotomous; (1) type I, (2) type II), treatment regimen (dichoto-
mous; (0) oral medication, (1) insulin), time since diagnosis in years (continuous), complications
(dichotomous; (0) no complications, (1) one or more complications), comorbidities (dichotomous;
(0) no comorbidities, (1) one or more comorbidities), HbA1c values (continuous), and diabetes-
related distress (continuous). All variables, except for diabetes-related distress, were retrieved from
patients’ records. In case we had no access to the record, this information was added from self-
report. Diabetes-related distress was measured by The Problem Areas In Diabetes (PAID) [44,45].
The internal consistency of the PAID was high in the current study (α = 0.95).
Sample size calculation
The sample size calculation was based on the primary aim of the original RCT to test the effec-
tiveness of CBT and MBCT in comparison to a waiting list control conditions. Assuming a sta-
tistical power of 0.8 and an alpha of 0.05, 42 participants were required in each group enabling
us to detect differences with an effect size of 0.6 [46]. As the current study is a secondary analy-
sis of the original RCT, results are regarded as exploratory.
Data analyses
Internal consistency of the questionnaires was tested by calculating Cronbach’s alpha. Signifi-
cant preexisting differences between the CBT and MBCT condition were examined by means
of t-tests and chi square tests. Analyses were conducted according to the intention-to-treat
approach. Missing values were imputed by means of multiple imputations using the Fully
Conditional Specification (FCS) method computing five imputed datasets. All analyses were
performed using SPSS 23 (see S1 Table for the dataset).
Along with other assumptions, data were checked on multicollinearity. The Variance Infla-
tion Factor (VIF) together with value of tolerance were inspected for continuous variables and
the phi-coefficient for categorical variables. A VIF above 10 and a phi above 0.3 are considered
as indicators of multicollinearity.
To investigate which patient characteristics predicted and moderated treatment outcome,
hierarchical linear regression analyses were conducted including post-treatment BDI-II scores
(severity of depressive symptoms) as the dependent variable.
We analyzed potential predictors stepwise. First, we evaluated potential prescriptive predic-
tors (moderators) of CBT and MBCT. For each domain, a model was generated including pre-
treatment BDI-II, condition ((1) CBT or (0) MBCT), possible confounding factors, and poten-
tial predictors in the first block. The condition x potential predictor interactions were entered
in the second block. Next, all significant (alpha 0.05) predictor effects from the different
domains (both main and interaction effects) were analyzed in one model to account for poten-
tial confounding effects of other predictors.
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In case of a significant interaction effect, separate regression analyses were performed for
each condition, including post-treatment BDI-II as dependent variable, pre-treatment BDI-II
scores, possible confounding factors, and the predictor.
Second, we investigated significant main effects in the final model as prognostic predictors.
Significant effects were examined separately for CBT and MBCT to assess whether the prog-
nostic predictor was found irrespective of or in relation to treatment.
We chose to investigate effects in a multivariate approach by selecting different domains in
order to reduce inflations of probability of making Type 1 error. To decrease the risk of over-
compensation, an alpha of 0.05 was considered statistically significant.
Between-group effect sizes were calculated using Cohen d, with values ranging from 0.2 to
0.5 indicating small effects, values from 0.5 to 0.8 indicating moderate effects, and values > 0.8
indicating large effects [47]. Moderating effects were illustrated in plots of predicted values
using Microsoft PowerPoint 2010.
In order to examine whether the effects remained present over time, all analyses were
repeated with the BDI-II scores at 9-months follow-up as the dependent variable.
Results
Patient characteristics
The sample consisted of 91 Caucasian participants. Patient characteristics are presented in
Table 1. Overall, participants had a mean age of 53, 50% was female, and most patients were in
a relationship. There was chance baseline imbalance between groups on several variables. Par-
ticipants randomized to the CBT condition were older, more likely to have one or more
comorbidities, and scored lower on neuroticism as compared to the MBCT condition. These
variables were controlled for in relevant analyses by including them as a main effect.
Prescriptive predictors of change
Data were assessed on multicollinearity. All VIF scores were below 10, indicating no multicol-
linearity for continuous variables. Type of diabetes and diabetes treatment and type of diabetes
and diabetes comorbidity had a phi-coefficient slightly above 0.3 (0.308 and 0.310). Consider-
ing that type of diabetes and insulin are also theoretically closely related constructs, yet type of
diabetes and diabetes comorbidity not necessarily, we decided to remove diabetes treatment
from the analyses.
Fifteen different putative predictors were investigated in three different domains. In the
final model combining all significant effects of the analyses within the three domains, a main
effect was found for history of care (b = 4.11, SE = 1.64, p = 0.013) and one interaction effect
for condition x education (dummy high levels of education; b = 8.17, SE = 3.54, p = 0.021) at
post-treatment. For interpretation of the results, means for depressive symptoms and effect
sizes of significant predictors are shown in Table 2.
The interaction effect showed that individuals with high levels of education as compared to
individuals with medium or lower levels benefitted less from treatment in the CBT condition
than in the MBCT condition (see also Fig 2). Thus, directly after treatment, MBCT might be
more advantageous than CBT for individuals with higher levels of educational attainment.
Investigating the effect of education on post-treatment depressive symptoms separately for
CBT and MBCT revealed that it remained a significant predictor within the CBT condition
(b = 7.51, SE = 2.98, p = 0.012), but not within the MBCT condition (b = -1.54, SE = 2.56,
p = 0.55). At 9-months follow-up, no significant effects were found, neither main effects, nor
interaction effects.
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Prognostic predictors of change
The significant main effect from the final prescriptive model was further investigated to assess
whether the effect was generally prognostic and thus irrespective of treatment, or significant
only for one treatment. Treatment specific analyses showed that history of care was a
Table 1. Patient characteristics.
Total (n = 91) CBT (n = 45) MBCT (n = 46)
Age (years) M (SD)* 53.2 (11.9) 56.1 (10.5) 50.4 (12.7)
Gender n (%)
Male 45 (50%) 21 (47%) 24 (52%)
Female 46 (50%) 24 (53%) 22 (48%)
Education n (%)
Lower levels vocational school 21 (23%) 12 (27%) 9 (19%)
Secondary education/advanced level vocational school 52 (57%) 25 (55%) 27 (59%)
Higher or University education 18 (20%) 8 (18%) 10 (22%)
Employment n (%)
Unemployed 39 (43%) 20 (44%) 19 (41%)
Employed 52 (57%) 25 (56%) 27 (59%)
Marital status n (%)
Not in a relationship 25 (27%) 15 (33%) 10 (22%)
In a relationship 66 (73%) 30 (67%) 36 (78%)
Type of diabetes n (%)
Type I 35 (39%) 13 (29%) 22 (48%)
Type II 56 (61%) 32 (71%) 24 (52%)
Diabetes treatment n (%)
Oral medication only 12 (13%) 7 (16%) 5 (11%)
Insulin 79 (87%) 38 (84%) 41 (89%)
Time since diagnosis (years) M (SD) 16.7 (12.0) 16.5 (12.6) 16.8 (11.6)
Diabetes complications n (%)**
No complications 60 (66%) 27 (60%) 33 (72%)
One or more complications 31 (34%) 18 (40%) 13 (28%)
Comorbidity n (%)*
No comorbidity 42 (46%) 16 (36%) 26 (57%)
One or more comorbidities 49 (54%) 29 (64%) 20 (43%)
IFCC HbA1c mmol/mol M (SD) 63.0 (12.4) 64.3 (14.6) 61.7 (9.8)
Diabetes-related distress M (SD) 38.8 (21.3) 39.8 (22.3) 37.7 (21.3)
Current depression n (%)
No major depression 67 (74%) 30 (67%) 37 (80%)
Major depression 24 (26%) 15 (33%) 9 (20%)
History of depression n (%)
No history 50 (55%) 23 (51%) 27 (59%)
History 41 (45%) 22 (49%) 19 (41%)
History of care n (%)
No history 46 (51%) 25 (56%) 21 (46%)
History 45 (49%) 20 (44%) 25 (54%)
Neuroticism M (SD)* 40.8 (6.6) 39.5 (6.1) 42.2 (6.8)
* significant differences between the groups at p < 0.05.
** included diabetes complications are: retinopathy, neuropathy, nephropathy, and diabetic foot.
https://doi.org/10.1371/journal.pone.0179941.t001
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significant predictor in both conditions (CBT: b = 4.66, SE = 2. 34, p = 0.047; MBCT: b = 7.13,
SE = 1.92, p< 0.001). These results imply that individuals with a history of psychological treat-
ment had less strong treatment effects as compared to individuals who did not receive prior
care.
Discussion
The main purpose of the present study was to investigate whether subgroups of patients with
diabetes and comorbid depressive symptoms could be identified that benefitted more from
CBT than from MBCT or vice versa. Educational attainment was the only factor that differen-
tially predicted treatment outcomes. The subgroup of individuals with higher educational
attainment (relative to individuals with medium or lower levels) reported more favorable out-
comes in the MBCT condition than in the CBT condition at post-treatment. This effect was
found directly after treatment and did not sustain at 9-months follow-up. For all other demo-
graphics, disease-related characteristics, clinical and personality factors, no moderating effects
were found. With respect to prognostic predictors (i.e. predictors within treatment condi-
tions), individuals with a history of psychological or psychiatric treatment (relative to those
without a history of care) had poorer treatment outcomes in CBT and MBCT. Again, this
effect was only evident directly after the intervention and did not remain at 9-months follow-
up.
One finding is that level of education was found as a prescriptive predictor of treatment
outcome in CBT and MBCT directly after the intervention. Yet, education could not be identi-
fied as prognostic predictor within the MCBT condition, but only within the CBT condition.
As noted in the introduction, earlier studies that directly compared CBT and MBCT investi-
gated only clinical factors and overlooked other potential prescriptive predictors such as
demographics and personality. Previous investigations comparing CBT with Interpersonal
Psychotherapy (IPT) or examining CBT and MCBT separately, have neither found that educa-
tion was a prescriptive nor a prognostic predictor of treatment outcome [26,48,49]. As our
findings are inconsistent with findings of earlier studies and as the effect was only temporary,
it might be due to chance. Replication of this result with a larger sample size is needed to esti-
mate the magnitude of our finding.
Table 2. Mean depression scores for levels of education and history of care, separately for CBT and MBCT on all measurements.
Group T1* T2 T3 Cohen’s d T1-T2 (95%CI) Cohen’s d T1-T3 (95%CI)
M (sd) M (sd) M (sd)
Education
Low levels CBT 26.4 (10.9) 19.0 (13.0) 20.3 (9.9) 0.62 (-0.2–1.4) 0.59 (-0.2–1.4)
MBCT 25.9 (4.9) 22.6 (9.2) 23.8 (12.2) 0.45 (-0.5–1.4) 0.22 (-0.7–1.1)
Medium levels CBT 24.2 (7.0) 14.9 (8.2) 17.6 (10.3) 1.23 (0.6–1.8) 0.75 (0.2–1.3)
MBCT 24.8 (9.3) 17.8 (11.2) 16.4 (10.4) 0.68 (0.1–1.2) 0.85 (0.3–1.4)
High levels CBT 23.5 (8.6) 21.7 (12.4) 19.8 (14.1) 0.17 (-0.8–1.1) 0.32 (-0.7–1.3)
MBCT 21.0 (7.8) 12.4 (11.0) 11.7 (7.1) 0.90 (-0.1–1.8) 1.24 (0.2–2.1)
History of care
No history CBT 24.4 (7.8) 14.9 (9.7) 18.1 (10.5) 1.09 (0.5–1.7) 0.68 (0.1–1.2)
MBCT 25.5 (9.4) 15.1 (11.7) 15.5 (12.3) 0.98 (0.3–1.6) 0.91 (0.3–1.5)
History CBT 25.0 (9.1) 20.1 (11.1) 19.5 (11.3) 0.49 (-0.2–1.1) 0.54 (-0.1–1.2)
MBCT 23.1 (7.4) 19.6 (10.3) 18.0 (9.6) 0.39 (-0.2–0.9) 0.60 (0.0–1.2)
* Measurements: T1 = pre-treatment, T2 = post-treatment, T3 = 9-months follow-up.
https://doi.org/10.1371/journal.pone.0179941.t002
What works best for whom? CBT and MBCT for depression in diabetes
PLOS ONE | https://doi.org/10.1371/journal.pone.0179941 June 29, 2017 10 / 16
A prognostic predictor irrespective of treatment condition was history of psychological
treatment. Patients who received psychological or psychiatric therapy prior to the study had
on average lower improvements in depression scores after treatment. Again, when investigat-
ing long-term effectiveness, history of treatment did not have an effect. To the best of our
knowledge, no existing study investigated the predictive effects of history of psychological
treatment. Strikingly, history of recurrent episodes of depression did not predict response to
CBT or MBCT in the current study. Also, history of treatment was not related to history of
depression, therefore it is unclear whether previous treatment was related to a depressive epi-
sode or other psychological problems. Accordingly, more research is needed to assess the pre-
dictive influence of history of psychological treatment and care on the effectiveness of CBT
and MCBT.
An important observation from this study is that only one prognostic predictor of treat-
ment outcome could be identified, which, in addition, was solely significant immediately after
Fig 2. Education as a moderator of depression (BDI-II). CBT = cognitive behavior therapy; MBCT = mindfulness-based cognitive therapy; T1 = pre-
treatment, T2 = post-treatment, T3 = at 9-months follow-up.
https://doi.org/10.1371/journal.pone.0179941.g002
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treatment and not at 9-months follow-up. Consistent with previous research [30,33], most
demographics, clinical characteristics, or diabetes related characteristics did not moderate or
predict outcome. Thus, there was no evidence that either CBT or MBCT was more effective for
individuals with certain age, gender, marital status, type of diabetes, or diabetes-related dis-
tress. In addition, current results add to the body of research proposing that presence of major
depression and history of depressive episode neither moderate nor predict outcome [34,50–
53]. This finding seems to be in contradiction with previous MBCT literature stating that
MBCT is only effective in preventing recurrence of depression in patients with three or more
previous depressive episodes [36,37] and in line with a study finding that MCBT was also effec-
tive for individuals with one or two prior episodes [54]. Yet, those studies focused on recur-
rently depressed patients in remission, whereas the current study investigated patients with
current depressive symptoms.
Another main finding was that, in contradiction with our hypothesis, neuroticism neither
moderated nor predicted the effects of CBT and MBCT. Whereas some research suggests a
tendency to attribute high levels of neuroticism to disadvantageous CBT outcomes [30–32]
and beneficial MBCT outcomes [38], other studies cannot validate this trend [30,35]. Those
studies were, however, not conducted in patients with diabetes. In a recent study in patients
with diabetes, negative affect, a concept closely related to neuroticism, was not identified as a
predictor [35]. It is therefore not surprising that our study found no effect.
A plausible explanation of current findings is that CBT and MBCT are accessible interven-
tions that are effective for a broad population of patients with diabetes, including for example
old and young people and individuals with severe or mild symptoms. Nevertheless, it could be
possible that other factors that are less easy to assess for clinicians, such as attachment style, or
coping style would differentially predict treatment outcome. Given the scarcity of previous
research comparing CBT and MBCT, more studies are needed to explore other potential prog-
nostic factors and draw firm conclusions.
As CBT and MBCT are general, not diabetes specific interventions to improve depressive symp-
toms, we believe that current findings can be generalized to other populations. No diabetes specific
characteristic was identified as a prognostic predictor, which might indicate that disease related
characteristics are less important in choosing the most effective treatment for a given person.
The main limitations of the randomized trial (as also discussed in our earlier paper) include
an underpowered sample size and relatively high attrition rates [16]. The current study is
therefore likely to be underpowered and analyses are seen as exploratory. Another limitation
of this study is that history depression and treatment were assessed by means of self-report,
which has possibly resulted in bias.
Conclusion
The current study is the first to directly compare a range of prognostic and prescriptive predic-
tors for CBT and MBCT for the treatment of depressive symptoms in patients with diabetes.
As both CBT and MBCT are effective interventions for reducing depressive symptoms, identi-
fying for whom which treatment may be the most beneficial has implications for clinical deci-
sion making. Despite examining a large number of potential prognostic and prescriptive
predictors, only few variables influenced treatment response and the effects did not sustain in
the long term. These results suggest that patient characteristics only make a modest contribu-
tion to treatment outcome and that both treatments are effective for individuals with different
characteristics. Future research could consider the contribution of other plausible prognostic
factors, or map differences in the therapeutic process, to further advance our understanding of
differential response to psychotherapy.
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